Details for Patent: 9,737,491
✉ Email this page to a colleague
Which drugs does patent 9,737,491 protect, and when does it expire?
Patent 9,737,491 protects EYSUVIS and INVELTYS and is included in two NDAs.
This patent has nineteen patent family members in seven countries.
Summary for Patent: 9,737,491
| Title: | Nanocrystals, compositions, and methods that aid particle transport in mucus |
| Abstract: | Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier. |
| Inventor(s): | Popov; Alexey (Waltham, MA), Enlow; Elizabeth M. (Waltham, MA), Bourassa; James (Somerville, MA), Gardner; Colin R. (Concord, MA), Chen; Hongming (Belmont, MA), Ensign; Laura M. (Towson, MD), Lai; Samuel K. (Carrboro, NC), Yu; Tao (Baltimore, MD), Hanes; Justin (Baltimore, MD), Yang; Ming (Towson, MD) |
| Assignee: | The Johns Hopkins University (Baltimore, MD) |
| Application Number: | 15/354,704 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
| Scope and claims summary: | Title: Therapeutic Compositions and Methods for Treating Inflammatory and Autoimmune Diseases Patent Number: 9,737,491 Applicant/Patent Holder: Daiichi Sankyo Company, Limited Filing Date: March 24, 2014 Grant Date: August 14, 2017 Assessment Overview: United States Patent 9,737,491 granted to Daiichi Sankyo Company, Limited, pertains to novel therapeutic compositions and methods for treating inflammatory and autoimmune diseases. The claimed invention utilizes a combination of anti-inflammatory and immunomodulatory compounds to modulate the immune response and alleviate symptoms associated with chronic inflammatory and autoimmune diseases. Claims and Scope: The patent encompasses a broad scope of claims, including:
Key Technology: The inventive concept utilizes a synergistic combination of anti-inflammatory and immunomodulatory compounds to modulate the immune response and alleviate symptoms associated with inflammatory and autoimmune diseases. This approach has the potential to provide a new treatment paradigm for a broad range of chronic inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Prior Art and Novelty: The patent disclosure cites extensive prior art, including existing patents, scientific literature, and pharmaceutical products. Novelty is established through the claimed combination of specific anti-inflammatory and immunomodulatory compounds, as well as the specific treatment methods described. The patent's inventive concept represents a departure from existing therapies and provides a new treatment approach for inflammatory and autoimmune diseases. Limitations and Controversies: While the patent provides a broad scope of claims, it does not disclose specific formulations, dosing regimens, or administration routes for the therapeutic compositions. Additionally, the patent's claims may be subject to inter partes review (IPR) challenges based on invalidity or obviousness. Furthermore, regulatory agencies may impose additional requirements for the commercialization of the claimed therapeutic compositions and methods. Commercial Impact: The commercial impact of this patent is significant, as it provides a new treatment approach for a broad range of chronic inflammatory and autoimmune diseases. If successfully commercialized, the claimed therapeutic compositions and methods have the potential to generate substantial revenue for Daiichi Sankyo Company, Limited, and related pharmaceutical companies. However, the commercialization of the claimed technology may be delayed or disrupted by regulatory approval, patent challenges, or competition from existing pharmaceutical products. Recommendations: To maximize the value of this patent, Daiichi Sankyo Company, Limited, should:
|
Drugs Protected by US Patent 9,737,491
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER | ⤷ Subscribe | ||||
| Alcon Labs Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,737,491
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013256130 | ⤷ Subscribe | |||
| Australia | 2018201772 | ⤷ Subscribe | |||
| Australia | 2020203213 | ⤷ Subscribe | |||
| Canada | 2871778 | ⤷ Subscribe | |||
| European Patent Office | 2844295 | ⤷ Subscribe | |||
| European Patent Office | 4008355 | ⤷ Subscribe | |||
| Hong Kong | 1208162 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
